Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press2710.17650/2222-8721-2014-0-3-28-41ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯUse of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsyПрименение препарата ботулинического токсина типа А (Ботокс) в лечении детского церебрального параличаKurenkovA. L.КуренковА. Л.
Russian Federation
alkurenkov@gmail.comKlochkovaO. A.КлочковаО. А.
Russian Federation
BursagovaB. I.БурсаговаБ. И.
Russian Federation
KuzenkovaL. M.КузенковаЛ. М.
Russian Federation
KarimovaKh. M.КаримоваХ. М.
Russian Federation
MamedyarovA. M.МамедьяровА. М.
Russian Federation
ArtemenkoA. R.АртеменкоА. Р.
Russian Federation
PetrovaS. A.ПетроваС. А.
Russian Federation
Research Center of Child Health, MoscowФГБНУ «Научный центр здоровья детей», МоскваI.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian FederationГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России190920144328411902201519022015Copyright ©; 2014, Kurenkov A.L., Klochkova O.A., Bursagova B.I., Kuzenkova L.M., Karimova K.M., Mamedyarov A.M., Artemenko A.R., Petrova S.A.Copyright ©; 2014, Куренков А.Л., Клочкова О.А., Бурсагова Б.И., Кузенкова Л.М., Каримова Х.М., Мамедьяров А.М., Артеменко А.Р., Петрова С.А.2014Kurenkov A.L., Klochkova O.A., Bursagova B.I., Kuzenkova L.M., Karimova K.M., Mamedyarov A.M., Artemenko A.R., Petrova S.A.Куренков А.Л., Клочкова О.А., Бурсагова Б.И., Кузенкова Л.М., Каримова Х.М., Мамедьяров А.М., Артеменко А.Р., Петрова С.А.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/27

Botulinum toxin type A (BoNT-A) is used in cerebral palsy (CP) for more than 20 years. Nevertheless, the unified protocol of injections and doses does not exist by now. The correct selection of target muscles for BoNT-A injections is based on the experience of the doctor, detailed analysis of neurological and orthopedic status of the patient, standard scales to evaluate motor potential of the patient. The article represents the detailed review of international clinical trials for multi-level use of BoNT-A in CP and recommendations on doses calculation. Based on our own observations of efficacy and safety of single-used doses of Botox we present the recommended dose ranges for upper and lower limb that led to clinically significant decrease of spasticity with no undesirable weakness. The review of clinical cases presents the doses per targeted muscle and total doses we used, they are advisory in nature.

botulinum toxin type Acerebral palsyspasticityspastic diplegiahemiparesisspastic tetraparesisneuroorthopedicsantispasticity medicationsgoals of treatmentAshworth scaleTardieu scaleGross motor function classification systemботулинический токсин типа Адетский церебральный параличспастичностьспастическая диплегиягемипарезспастический тетрапарезнейроортопедияантиспастические препаратыцели леченияшкала Эшворташкала Тардье1. Koman L.A., Mooney J.F. 3rd, Smith B. et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993;13(4):489–95.Koman L.A., Mooney J.F. 3rd, Smith B. et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993;13(4):489–95.2. Graham H.K., Aoki K.R., Autti-Ramo I. et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11: 67–79.Graham H.K., Aoki K.R., Autti-Ramo I. et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11: 67–79.3. Heinen F., Molenaers G., Fairhurst C. et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006;10(5–6):215–25.Heinen F., Molenaers G., Fairhurst C. et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006;10(5–6):215–25.4. Heinen F., Desloovere K., Schroeder A.S. et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010;14(1):45–66.Heinen F., Desloovere K., Schroeder A.S. et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010;14(1):45–66.5. Love S.C., Novak I., Kentish M. et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neur 2010;17(Suppl 2):9–37.Love S.C., Novak I., Kentish M. et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neur 2010;17(Suppl 2):9–37.6. Bax M., Goldstein M., Rosenbaum P. et al. Proposed definition and classification of cerebral palsy. Dev Med Child Neurol 2005;47(8):571–6.Bax M., Goldstein M., Rosenbaum P. et al. Proposed definition and classification of cerebral palsy. Dev Med Child Neurol 2005;47(8):571–6.7. Miller F. Cerebral palsy. New York: Springer Science, 2005. 1055 p.Miller F. Cerebral palsy. New York: Springer Science, 2005. 1055 p.8. Батышева Т.Т., Быкова О.В., Виноградов А.В. Приверженность семьи к лечению ребенка с неврологической патологией. Журн неврол и психиатр им. С.С. Корсакова 2012;7(2): 56–63.Батышева Т.Т., Быкова О.В., Виноградов А.В. Приверженность семьи к лечению ребенка с неврологической патологией. Журн неврол и психиатр им. С.С. Корсакова 2012;7(2): 56–63.9. Семенова К.А., Махмудова Н.М. Медицинская реабилитация и социальная адаптация больных детским церебральным параличом. Ташкент: Медицина, 1979. 487 с.Семенова К.А., Махмудова Н.М. Медицинская реабилитация и социальная адаптация больных детским церебральным параличом. Ташкент: Медицина, 1979. 487 с.10. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42(12):816–24.Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42(12):816–24.11. Palisano R., Rosenbaum P., Walter S. et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol1997;39(4):214–23.Palisano R., Rosenbaum P., Walter S. et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol1997;39(4):214–23.12. Palisano R.J. A collaborative model of service delivery for children with movement disorders: a framework for evidence-based decision making. Phys Ther 2006;86(9): 1295–305.Palisano R.J. A collaborative model of service delivery for children with movement disorders: a framework for evidence-based decision making. Phys Ther 2006;86(9): 1295–305.13. Hanna S.E., Rosenbaum P.L., Bartlett D.J. et al. Stability and decline in gross motor function among children and youth with cerebral palsy aged 2 to 21 years. Dev Med Child Neurol 2009;51(4):295–302.Hanna S.E., Rosenbaum P.L., Bartlett D.J. et al. Stability and decline in gross motor function among children and youth with cerebral palsy aged 2 to 21 years. Dev Med Child Neurol 2009;51(4):295–302.14. Eliasson A.C., Krumlinde-Sundholm L., Rösblad B. et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006;48(7):549–54.Eliasson A.C., Krumlinde-Sundholm L., Rösblad B. et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006;48(7):549–54.15. Hidecker M.J., Paneth N., Rosenbaum P.L. et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011;53(8):704–10.Hidecker M.J., Paneth N., Rosenbaum P.L. et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011;53(8):704–10.16. Hidecker M.J., Ho N.T., Dodge N. et al. Inter-relationships of functional status in cerebral palsy: analyzing gross motor function, manual ability, and communication function classification systems in children. Dev Med Child Neurol 2012;54(8):737–42.Hidecker M.J., Ho N.T., Dodge N. et al. Inter-relationships of functional status in cerebral palsy: analyzing gross motor function, manual ability, and communication function classification systems in children. Dev Med Child Neurol 2012;54(8):737–42.17. Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2): 206–7.Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2): 206–7.18. Boyd R.N., Graham H.K. Objective measurement of clinical findings in the use of Botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6(Suppl. 4):23–35.Boyd R.N., Graham H.K. Objective measurement of clinical findings in the use of Botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6(Suppl. 4):23–35.19. Gage J.R., Stout J.L. Gait analysis: kinematics, kinetics, electromyography, oxygen consumption and pedobarography. In: The identification and treatment of gait problems in cerebral palsy (Eds. Gage J.R., Schwartz M.H., Koop S.E., Novacheck T.F.). London: Mac Keith Press, 2009. P. 260–284.Gage J.R., Stout J.L. Gait analysis: kinematics, kinetics, electromyography, oxygen consumption and pedobarography. In: The identification and treatment of gait problems in cerebral palsy (Eds. Gage J.R., Schwartz M.H., Koop S.E., Novacheck T.F.). London: Mac Keith Press, 2009. P. 260–284.20. Leonard J., Graham H.K. Treatment of motor disorders in cerebral palsy with bo tulinum neurotoxin. In book: Botulinum toxin: Therapeutic clinical practice and science (Ed. by J. Jankovic). Philadelphia: Saunders Elsevier, 2009. P. 172–191.Leonard J., Graham H.K. Treatment of motor disorders in cerebral palsy with bo tulinum neurotoxin. In book: Botulinum toxin: Therapeutic clinical practice and science (Ed. by J. Jankovic). Philadelphia: Saunders Elsevier, 2009. P. 172–191.21. Simpson D.M., Gracies J.M., Graham H.K. et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1691–8.Simpson D.M., Gracies J.M., Graham H.K. et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1691–8.22. Delgado M.R., Hirtz D., Aisen M. et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74(4):336–43.Delgado M.R., Hirtz D., Aisen M. et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74(4):336–43.23. Hoare B.J., Wallen M.A., Imms C. et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; (1):CD003469.Hoare B.J., Wallen M.A., Imms C. et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; (1):CD003469.24. Sakzewski L., Ziviani J., Boyd R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics 2009;123(6):1111–22.Sakzewski L., Ziviani J., Boyd R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics 2009;123(6):1111–22.25. Артеменко А.Р., Куренков А.Л. Ботулинический токсин: вчера, сегодня, завтра. Нервно-мышечные болезни 2013;2:6–18.Артеменко А.Р., Куренков А.Л. Ботулинический токсин: вчера, сегодня, завтра. Нервно-мышечные болезни 2013;2:6–18.26. Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol 2012;15(3):325–36.Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol 2012;15(3):325–36.27. Burgen A., Dickens F., Zatman L.J. The action of botulinum toxin on the neuromusculat junction. J Phisiol 1949;109:10–24.Burgen A., Dickens F., Zatman L.J. The action of botulinum toxin on the neuromusculat junction. J Phisiol 1949;109:10–24.28. Grissom J.R. Chemical denervation. In book: Electrodiagnostic medicine, 2nd edition (Eds. D. Dumitru, M.J. Zwarts, A.A. Amato). Philadelphia: Hanley & Belfus, Inc., 2002. P. 479–512.Grissom J.R. Chemical denervation. In book: Electrodiagnostic medicine, 2nd edition (Eds. D. Dumitru, M.J. Zwarts, A.A. Amato). Philadelphia: Hanley & Belfus, Inc., 2002. P. 479–512.29. Куренков А.Л., Артеменко А.Р., Никитин С.С., Орлова О.Р. Современные представления о механизмах действия ботулинического токсина типа А. Врач 2009;7:8–12.Куренков А.Л., Артеменко А.Р., Никитин С.С., Орлова О.Р. Современные представления о механизмах действия ботулинического токсина типа А. Врач 2009;7:8–12.30. Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997;152: 132–5.Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997;152: 132–5.31. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005;63:180–5.Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005;63:180–5.32. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43 (Suppl. 1): 9–15.Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43 (Suppl. 1): 9–15.33. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26 (5):785–93.Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26 (5):785–93.34. Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51 (10):1573–7.Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51 (10):1573–7.35. Gazerani P., Pedersen N.S., Staahl C. et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141(1–2):60–9.Gazerani P., Pedersen N.S., Staahl C. et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141(1–2):60–9.36. Dolly J.O., O’Connell M.A. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012;12:100–8.Dolly J.O., O’Connell M.A. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012;12:100–8.37. Sutherland D.H., Kaufman K.R., Wyatt M.P. et al. Double-blind study of botulinum toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait and Posture 1999;10:1–9.Sutherland D.H., Kaufman K.R., Wyatt M.P. et al. Double-blind study of botulinum toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait and Posture 1999;10:1–9.38. Koman L.A., Mooney J.F. 3rd, Smith B.P. et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20(1):108–15.Koman L.A., Mooney J.F. 3rd, Smith B.P. et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20(1):108–15.39. Love S.C., Valentine J.P., Blair E.M. et al. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol 2001;8 (Suppl 5): 50–8.Love S.C., Valentine J.P., Blair E.M. et al. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol 2001;8 (Suppl 5): 50–8.40. Corry I.S., Cosgrove A.P., Duffy C.M. et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18(3): 304–11.Corry I.S., Cosgrove A.P., Duffy C.M. et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18(3): 304–11.41. Kirschner J., Berweck S., Mall V. et al. Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol 2001;248(Suppl 1):28–30.Kirschner J., Berweck S., Mall V. et al. Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol 2001;248(Suppl 1):28–30.42. Koman L.A., Paterson Smith B., Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 2003;5(1):11–23.Koman L.A., Paterson Smith B., Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 2003;5(1):11–23.43. Naumann M., Albanese A., Heinen F. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 (Suppl 4):35–40.Naumann M., Albanese A., Heinen F. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 (Suppl 4):35–40.44. Howell K., Selber P., Graham H.K., Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007;43(6):499–501.Howell K., Selber P., Graham H.K., Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007;43(6):499–501.45. Crowner B.E., Brunstrom J.E., Racette B.A. Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol 2007;30(5):310–3.Crowner B.E., Brunstrom J.E., Racette B.A. Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol 2007;30(5):310–3.46. Sätilä H.K., Pietikäinen T., Lehtonen-Räty P. et al. Treatment of spastic equinus gait with botulinum toxin A: Does dose matter? Analysis of a clinical cohort. Neuropediatrics 2006;37(6):344–9.Sätilä H.K., Pietikäinen T., Lehtonen-Räty P. et al. Treatment of spastic equinus gait with botulinum toxin A: Does dose matter? Analysis of a clinical cohort. Neuropediatrics 2006;37(6):344–9.47. Willis A.W., Crowner B., Brunstrom J.E. et al. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 2007;49(11):818–22.Willis A.W., Crowner B., Brunstrom J.E. et al. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 2007;49(11):818–22.48. Molenaers G., Schörkhuber V., Fagard K. et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol 2009;13(5): 421–9.Molenaers G., Schörkhuber V., Fagard K. et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol 2009;13(5): 421–9.49. Инструкция по применению лекарственного препарата для лекарственного применения Ботокс 100 ЕД. Регистрационный номер: П №011936/01, 2013.Инструкция по применению лекарственного препарата для лекарственного применения Ботокс 100 ЕД. Регистрационный номер: П №011936/01, 2013.